Metagenomi, Inc. Common Stock (MGX)
$
1.62
-0.05 (-3.09%)
Key metrics
Financial statements
Free cash flow per share
-2.8243
Market cap
62.1 Million
Price to sales ratio
1.3709
Debt to equity
0.2090
Current ratio
5.8455
Income quality
1.3094
Average inventory
0
ROE
-0.3205
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Metagenomi, Inc. is a gene editing biotechnology company based in Emeryville, California, that develops therapeutics aimed at improving patient outcomes through its metagenomics-derived genome editing toolbox. The toolbox features advanced technologies such as programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. The company reported an operating income of -$88,901,000.00 reflecting its earnings from core operations, while the EBITDA is -$83,494,000.00 a key indicator of the company's operational profitability. The gross profit ratio is $0.90 which highlights the efficiency of Metagenomi's production and sales operations. In terms of financial dynamics, the company earned an interest income of $14,722,000.00 showcasing its financial investments. However, it also faced challenges, reporting a net loss of -$78,058,000.00 which indicates difficulties in its operations. Metagenomi has formed a strategic collaboration and license agreement with ModernaTX, Inc. to focus on a novel genome editing system for in vivo human therapeutic applications. Additionally, the company has entered into a development, option, and license agreement with Affini-T Therapeutics, Inc. to pursue gene-edited T-cell receptor-based therapeutic products aimed at the treatment, prevention, or diagnosis of human cancer. Furthermore, a collaboration and license agreement with Ionis Pharmaceuticals, Inc. aims to research, develop, and commercialize investigational medicines utilizing genome editing technologies. With the stock being affordable at $1.67 it presents an opportunity for budget-conscious investors. The stock has a high average trading volume of 376,634.00 which indicates strong liquidity in the market. With a market capitalization of $60,558,024.00 the company is classified as a small-cap player and is recognized as a key contributor in the Biotechnology industry, significantly influencing the overall market landscape. Additionally, it belongs to the Healthcare sector, driving innovation and growth, thereby positioning itself as a pivotal participant in the biotechnology sector focused on genome editing.
Is Metagenomi, Inc. Common Stock (MGX) a good investment?
Investing in Metagenomi, Inc. Common Stock (MGX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Metagenomi, Inc. Common Stock (MGX)'s stock forecast?
Analysts predict Metagenomi, Inc. Common Stock stock to fluctuate between $1.23 (low) and $6.90 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Metagenomi, Inc. Common Stock's market capitalization?
As of 2025-05-23, Metagenomi, Inc. Common Stock's market cap is $60,558,024, based on 37,381,496 outstanding shares.
How does Metagenomi, Inc. Common Stock compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Metagenomi, Inc. Common Stock has a Lower Market-Cap, indicating a difference in performance.
How can I buy Metagenomi, Inc. Common Stock (MGX) stock?
To buy Metagenomi, Inc. Common Stock (MGX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for MGX. Place an order (Market, Limit, etc.).
What is the best time to invest in Metagenomi, Inc. Common Stock?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Metagenomi, Inc. Common Stock perform in the last earnings report?
Revenue: $52,295,000 | EPS: -$2.36 | Growth: 29.67%.
Where can I find Metagenomi, Inc. Common Stock's investor relations reports?
Visit https://www.metagenomi.co/investor-relations for detailed financial reports.
Where can I find historical stock prices for Metagenomi, Inc. Common Stock?
You can explore historical data from here
What is the all-time high and low for Metagenomi, Inc. Common Stock stock?
All-time high: $12.74 (2024-02-15) | All-time low: $1.23 (2025-04-04).
What are the key trends affecting Metagenomi, Inc. Common Stock stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
13 days ago
- Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a critical milestone for the treatment of neurological disorders -
zacks.com
13 days ago
Metagenomi (MGX) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $1.19 per share a year ago.
globenewswire.com
13 days ago
- Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximate ly 19 months with an encouraging safety profile
globenewswire.com
25 days ago
EMERYVILLE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that the Company will present at two upcoming scientific meetings: an oral presentation at TIDES USA 2025, taking place May 19-22, 2025, at the Manchester Grand Hyatt San Diego, and three poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting, taking place May 13-17, 2025, in New Orleans, LA and virtually.
globenewswire.com
2 months ago
Hemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII (FVIII) activity in nonhuman primate (NHP) study for more than 16 months
globenewswire.com
2 months ago
Achieved targeted integration of a large, therapeutically relevant gene into the genome of human cells with compact CAST system AI-driven metagenomics platform facilitated discovery of CAST system with activity in human cells Expression of the compact CAST system from a single 'all-in-one' mRNA design represents a first-in-class approach to simplifying delivery for therapeutic applications Additional updates on further advancements in novel large gene integration technology anticipated in 2025 EMERYVILLE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced a publication in the journal Nature Communications describing its novel, compact CAST system for large, targeted gene integration into the human genome.
globenewswire.com
4 months ago
EMERYVILLE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that Brian C. Thomas, PhD, CEO and founder of Metagenomi, will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, 2025, from 1:10-1:40 p.m. ET in Boston. The company will host one-on-one investor meetings at the conference.
globenewswire.com
4 months ago
MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025 NHP Proof-of-Concept Anticipated for Secreted Protein Deficiency Platform in 2025 Leveraging MGX-001 Editing Approach On Track for One to Two Development Candidate Nominations in 2025 from Wave 1 Ionis Collaboration Programs Focusing on Cardiometabolic Indications Cash Runway Anticipated to Support Operating Plans into 2027 EMERYVILLE, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today provided updates on the successful achievement of critical milestones across its therapeutic development programs and technology platforms in 2024 and anticipated milestones for 2025 and 2026.
globenewswire.com
4 months ago
EMERYVILLE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that Eric Bjerkholt, MBA, CFO of Mirum Pharmaceuticals, Inc., will join Metagenomi's Board of Directors, serving on Metagenomi's Audit and Compensation committees, effective January 27, 2025.
globenewswire.com
5 months ago
EMERYVILLE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that Brian C. Thomas, PhD, CEO and founder of Metagenomi, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 4:30 p.m. PT in San Francisco.
See all news
